Evidence map›Paper›PMID 25812157›Full record

ArticlePloS one2015

Small RNA sequencing for profiling microRNAs in long-term preserved formalin-fixed and paraffin-embedded non-small cell lung cancer tumor specimens.

Daniel H Buitrago, Santosh K Patnaik, Kyuichi Kadota, Eric Kannisto, David R Jones, Prasad S Adusumilli

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. MicroRNAs as Biomarkers in Thyroid Carcinoma.International journal of genomics · 2017
    Review
  12. Tumour heterogeneity: principles and practical consequences.Virchows Archiv : an international journal of pathology · 2016
    Review
  13. Article
  14. MiRNA-323-5p Promotes U373 Cell Apoptosis by Reducing IGF-1R.Medical science monitor : international medical journal of experimental and clinical research · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Daniel H BuitragoThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Santosh K PatnaikDepartment of Thoracic Surgery, Roswell Park Cancer Institute, Buffalo, New York, United States of America.
Kyuichi KadotaThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Eric KannistoDepartment of Thoracic Surgery, Roswell Park Cancer Institute, Buffalo, New York, United States of America.
David R JonesThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Prasad S AdusumilliThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America; Center of Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Memorial Sloan Kettering Cancer Center · USRoswell Park Comprehensive Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Tumor Evolution and Changes in MetabolismP50CA086438 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI RIVIERI, ISABELLE · 2000 to 2015
$29.9M
Training and Career Development and Education CoreU54CA137788 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Daniel Alan Heller · 2008 to 2026
$28.1M
Epigenetic and post-translational regulation of the metastasis suppressor BRMS1R01CA136705 · NCI · UNIVERSITY OF VIRGINIA · PI JONES, DAVID R · 2009 to 2013
$1.5M
Validation of a risk model for stage I lung adenocarcinomaR21CA164568 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADUSUMILLI, PRASAD S., PATNAIK, SANTOSH KUMAR · 2012 to 2013
$432k
Mesothelin as a biomarker for clinical management of esophageal adenocarcinomaR21CA164585 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADUSUMILLI, PRASAD S., RIZK, NABIL · 2012 to 2013
$426k
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA086438NCI NIH HHS P50 CA086438-13NCI NIH HHS R01 CA136705NCI NIH HHS R01 CA136705-06NCI NIH HHS R21 CA164568NCI NIH HHS R21 CA164568-01A1NCI NIH HHS R21 CA164585NCI NIH HHS R21 CA164585-01A1NCI NIH HHS U54 CA137788
6 · The paper itself

Abstract

backgroundThe preservation of microRNAs in formalin-fixed and paraffin-embedded (FFPE) tissue makes them particularly useful for biomarker studies. The utility of small RNA sequencing for microRNA expression profiling of FFPE samples has yet to be determined.

methodsTotal RNA was extracted from de-paraffinized and proteinase K-treated FFPE specimens (15-20 years old) of 8 human lung adenocarcinoma tumors by affinity chromatography on silica columns. MicroRNAs in the RNA preparations were quantified by the Illumina HiSeq 2000 sequencing platform with sequencing libraries prepared with the TruSeq Small RNA Sample Preparation Kit (version 2.0) to obtain unpaired reads of 50 b for small RNA fragments. MicroRNAs were also quantified using Agilent Human miRNA (release 16.0) microarrays that can detect 1,205 mature microRNAs and by quantitative reverse transcription (RT)-PCR assays.

resultsBetween 9.1-16.9 million reads were obtained by small RNA sequencing of extracted RNA samples. Of these, only 0.6-2.3% (mean = 1.5%) represented microRNAs. The sequencing method detected 454-625 microRNAs/sample (mean = 550) compared with 200-349 (mean = 286) microRNAs detected by microarray. In Spearman correlation analyses, the average correlation coefficient for the 126 microRNAs detected in all samples by both methods was 0.37, and >0.5 for 63 microRNAs. In correlation analyses of the sequencing- and RT-PCR-based measurements, the coefficients were 0.19-0.95 (mean = 0.73) and >0.7, respectively, for 7 of 9 examined microRNAs. The average inter-replicate Spearman correlation coefficient for the sequencing method was 0.81.

conclusionsSmall RNA sequencing can be used to obtain microRNA profiles of FFPE tissue specimens with performance characteristics similar to those of microarrays, in spite of the fragmentation of ribosomal and messenger RNAs that reduces the method's informative capacity. The accuracy of the method can conceivably be improved by increasing sequencing depth and/or depleting FFPE tissue RNAs of ribosomal RNA fragments.

Indexed as

Sequence Analysis, RNACarcinoma, Non-Small-Cell LungGene Expression ProfilingHumansLung NeoplasmsMicroRNAsReproducibility of ResultsMicroRNAs

Identifiers

PMID25812157
PMCPMC4374839
OpenAlexW2010307819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.